EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens

Joseph Fokam iD, Collins Ambe Chenwi iD, Valère Tala, Désiré Takou, Maria Mercedes Santoro iD, George Teto, Beatrice Dambaya, Felix Anubodem, Ezechiel Ngoufack Jagni Semengue, Grace Beloumou, Sandrine Djupsa, Edgar Assomo und 10 weitere

Viruses · 2023

DOI: 10.3390/v15071458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Joseph Fokam und 21 weiteren Autor:innen. Beteiligte Einrichtung: Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Messa, Yaoundé P.O. Box 3077, Cameroon. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV-1. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chantal BIYA International Reference Center for Research on HIV and AIDS Prevention and Management (CIRCB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of first-line antiretroviral therapy (ART) may be hampered by the presence of HIV drug resistance (HIVDR). We described HIV-1 pre-treatment drug resistance (PDR) patterns, effect of viral clades on PDR, and programmatic implications on first-line regimens in Cameroon. A sentinel surveillance of PDR was conducted from 2014 to 2019. Sequencing of HIV-1 protease and reverse transcriptase was performed, and HIVDR was interpreted using Stanford HIVdb.v.9.4. In total, 379 sequences were obtained from participants (62% female, mean age 36 ± 10 years). The overall PDR rate was 15.0% [95% CI: 11.8–19.0] nationwide, with significant disparity between regions (p = 0.03). NNRTI PDR was highest (12.4%), of which 7.9% had DRMs to EFV/NVP. Two regions had EFV/NVP PDR above the 10% critical threshold, namely the Far North (15%) and East (10.9%). Eighteen viral strains were identified, predominated by CRF02_AG (65.4%), with no influence of genetic diversity PDR occurrence. TDF-3TC-DTG predictive efficacy was superior (98.4%) to TDF-3TC-EFV (92%), p < 0.0001. The overall high rate of PDR in Cameroon, not substantially affected by the wide HIV-1 genetic diversity, underscores the poor efficacy of EFV/NVP-based first-line ART nationwide, with major implications in two regions of the country. This supports the need for a rapid transition to NNRTI-sparing regimens, with TDF-3TC-DTG having optimal efficacy at the programmatic level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHIV-1HumansFemaleAdultMiddle AgedMaleCameroonAnti-Retroviral AgentsGenetic VariationDrug Resistance, Viral

Stichwörter der Autor:innen

CameroonHIV-1first-line regimensgenetic diversitypre-treatment drug resistance

Substanzen

Anti-HIV AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Messa, Yaoundé P.O. Box 3077, Cameroon.
  • Faculty of Health Science, University of Buea, Buea P.O. Box 0063, Cameroon.
  • Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé P.O. Box 1364, Cameroon.
  • National HIV Drug Resistance Prevention and Surveillance Working Group, Ministry of Public Health, Yaoundé P.O. Box 3038, Cameroon.
  • Department of Experimental Medicine, Faculty of Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
  • Faculty of Sciences and Technologies, Evangelical University of Cameroon, Bandjoun P.O. Box 0127, Cameroon.

ORCID-Profile: Joseph Fokam, Collins Ambe Chenwi, Maria Mercedes Santoro, Claudia Alteri

Förderung

  • Chantal BIYA International Reference Center for Research on HIV and AIDS Prevention and Management (CIRCB)

Zitieren

APA

Fokam, J., Chenwi, C. A., Tala, V., Takou, D., Santoro, M. M., Teto, G., Dambaya, B., Anubodem, F., Semengue, E. N. J., Beloumou, G., Djupsa, S., Assomo, E., Fokunang, C., Alteri, C., Billong, S., Bouba, N. P., Ajeh, R., Colizzi, V., Mbanya, D., …, & Ndjolo, A. (2023). Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens. Viruses. https://doi.org/10.3390/v15071458

Vancouver

Fokam J, Chenwi CA, Tala V, Takou D, Santoro MM, Teto G, et al. Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens. Viruses. 2023. doi:10.3390/v15071458

BibTeX
@article{Fokam2023,
  author = {Fokam, Joseph and Chenwi, Collins Ambe and Tala, Valère and Takou, Désiré and Santoro, Maria Mercedes and Teto, George and Dambaya, Beatrice and Anubodem, Felix and Semengue, Ezechiel Ngoufack Jagni and Beloumou, Grace and Djupsa, Sandrine and Assomo, Edgar and Fokunang, Charles and Alteri, Claudia and Billong, Serge and Bouba, Nounouce Pamen and Ajeh, Rogers and Colizzi, Vittorio and Mbanya, Dora and Ceccherini-Silberstein, Francesca and Perno, Carlo-Federico and Ndjolo, Alexis},
  title = {Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15071458}
}
Kostenlos starten →